Valbiotis Shares Drop 6% Following Announcement of a Dilutive Capital Increase
Valbiotis stock significantly suffers midday, penalized by investors following the announcement of a dilutive capital increase. The company is simultaneously trying to advance its international commercial development, in a Parisian market that is itself trending downward.
Valbiotis Shares Fall 6% to €0.94 During the Session
Valbiotis shares lose 6% to €0.94 during the session, in a downward trending Parisian market (CAC 40: -0.6%, SBF 120: -0.56%). The decline brings the weekly loss to nearly 19%.
The company announced this Monday a capital increase of €10.2 million with the maintenance of preferential subscription rights, secured at 76.6% through commitments and guarantees, including €2 million contributed by the co-founder of the Asian partner Aika. The dilutive effect mechanically explains the market reaction.
In parallel, the group signed an exclusive distribution agreement with Al Danah Medical Company in Qatar for four products, with first revenues expected in 2027. This commercial move has not been enough to offset the impact of the financial operation.
Support Level of €0.92 Breached During the Session, TP Icap Midcap Lowers Target to €2.10
The stock breached its support at €0.92 during the session, hitting a low at €0.89, before moving back above the threshold. The price is now trading below the MM20 (€1.09) and MM50 (€1.03), with respective gaps of -13.76% and -8.74%, indicating a short-term momentum degradation.
The RSI at 44 remains in the neutral zone despite selling pressure, indicating that the decline has not yet resulted in a technically oversold configuration. The MM200, at €0.85, remains 10.59% below the current price, anchoring the long-term trend.
Regarding recommendations, TP Icap Midcap adjusted its target today from €2.30 to €2.10, while maintaining a buy opinion. The new target leaves a substantial theoretical gap from the current price.
